Brad S. Kahl, MD, a professor in the Department of Medicine, Oncology Division, at Washington University School of Medicine in St. Louis, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma (MCL). The covalent BTK inhibitors zanubrutinib (Brukinsa) and acalabrutinib (Calquence) are currently approved by the FDA for […]
Blood Cancer © laszlo – stock.adobe.com Loncastuximab tesirine-lpyl (Zynlonta) plus rituximab (Rituxan; Lonca-R) demonstrated promising antitumor activity and consistent safety signals in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to updated data from the phase 3 LOTIS-5 trial (NCT04384484) that were presented at the 2023 SOHO Annual Meeting.1 As of the data cutoff […]
Harry P. Erba, MD, PhD The addition of quizartinib (Vanflyta) to induction and consolidation chemotherapy, followed by single-agent quizartinib for up to 36 cycles, improved survival outcomes vs placebo in patients with FLT3 ITD–mutated, newly diagnosed acute myeloid leukemia (AML), according to a presentation given by Harry P. Erba, MD, PhD at the 2023 SOHO Annual Meeting. […]
The National Comprehensive Cancer Network (NCCN®) today announced the publication of a new supportive care patient guideline focused on preventing and treating cancer-associated blood clots, also known as venous thromboembolism (VTE). Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer. Blood clots are a leading […]
The last few decades have brought remarkable advances in how blood cancers and serious blood disorders are treated. New types of medicines have changed some diseases, like chronic myeloid leukemia (CML), from acute – and often fatal – diagnoses into chronic conditions patients can live with for many years.1 Other areas of hematology research have […]
“We believe luspatercept provides clinical benefit regardless of subgroup and baseline mutation burden, and, therefore, we believe this now becomes the standard of care for the majority of our patients with lower-risk disease with anemia who are transfusion dependent,” according to Guillermo Garcia-Manero, MD, COMMANDS trial lead investigator and chief of the Section of Myelodysplastic […]
Mohammad Bakri Hammami, MD A retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) database emphasized the potential impact of specific socio-racial factors, such as race, sex, and age, on survival outcomes in patients with primary myelofibrosis, according to findings presented at the 2023 SOHO Annual Meeting. Data collected from the database between 2000 […]
Biopsy shows myelofibrosis | Image Credit: © tonaquatic – www.stock.adobe.com Retrospective research shows that race, sex, age, and other socio-racial factors can impact survival outcomes in patients with primary myelofibrosis, according to data presented at the 2023 Society of Hematologic Oncology (SOHO) Annual Meeting. Data collected from the Surveillance, Epidemiology, and End Results (SEER) database […]
Roland Walter, MD, PhD Allogeneic stem cell transplant (ASCT) is an important treatment for relapsed or refractory acute myeloid leukemia (AML). Reviewing the current research, experts are questioning the benefit of giving therapy before or after patients undergo ASCT. During a debate held at the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO […]
